Research presented at the 79th ADA Scientific Sessions in San Francisco, California, USA, suggests that high-intensity exercise can partially restore counterregulatory responses to hypoglycemia in people with impaired awareness of the condition.
Of the immunotherapies tested to date, teplizumab and low-dose antithymocyte globulin are the most promising for slowing the decline in C-peptide in people with newly diagnosed type 1 diabetes, researchers report.
Detailed analysis of renal outcomes in the DECLARE-TIMI 58 trial confirms that treatment with the sodium-glucose cotransporter 2 inhibitor dapagliflozin is renoprotective in patients with type 2 diabetes and preserved kidney function.
The glucagon-like peptide-1 receptor agonist dulaglutide has demonstrated significant cardioprotection in the REWIND trial, despite the trial population being lower risk than usual for cardiovascular outcome trials.
Patients with type 2 diabetes last for longer before needing treatment intensification if they are treated with fixed-ratio combination insulin degludec and liraglutide rather than insulin glargine 100 U/mL, show the DUAL VIII findings.
The latest analysis from the observational follow-up of the TODAY study participants shows rapid accumulation of cardiovascular risk factors and diabetes complications in people who were diagnosed with type 2 diabetes in youth.
Data from the phase IIIa PIONEER 2 and PIONEER 4 studies show that semaglutide equals or betters both empagliflozin and liraglutide for the reduction of glycated hemoglobin in patients with type 2 diabetes uncontrolled on metformin.
Findings from the GRAVITAS trial indicate that use of the GLP-1 receptor agonist liraglutide alongside a diet and physical activity intervention may improve glycemic control among people with persistent or recurrent type 2 diabetes after bariatric surgery.
Researchers have discovered an immune cell with the attributes of both B cells and T cells, which is present in increased frequency in some people with type 1 diabetes and capable of activating insulin-specific T-helper cells.